Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | KMT2A - MLLT1 |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
KMT2A - MLLT1 | acute lymphoblastic leukemia | predicted - sensitive | I-BET151 + Prednisolone | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with I-BET151 enhanced the efficacy of Omnipred (prednisolone) in acute lymphoblastic leukemia cells harboring a KMT2A-MLLT1 (also known as MLL-ENL) fusion, resulting in increased cell death compared to either therapy alone in culture (PMID: 29748211). | 29748211 | |
KMT2A - MLLT1 | acute myeloid leukemia | sensitive | MI-503 | Preclinical - Cell culture | Actionable | In a preclinical study, MI-503 inhibited growth of an acute myeloid leukemia cell line harboring KMT2A-MLLT1 (MLL-ENL) in culture (PMID: 25817203). | 25817203 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|